In recent trading, shares of Arrowhead Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $10.50, changing hands for $11.11/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on June 1, 2018, the Board of Directors approved "inducement" grants to 13 new employees under Rule 5635(c)(4) of the NASDAQ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the presentation of new preclinical data on ARO-ENaC, formerly referred to as ARO-Lung1, for the treatment of cystic fibrosis (CF), at the American Thoracic Society (ATS) 2018 International...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first 3 hepatitis B virus (HBV) patients in the multiple-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV, the company's third generation subcutaneously...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of new preclinical data on its expanding pipeline of RNA interference (RNAi) therapeutics for cardiometabolic diseases, including ARO-ANG3, which targets angiopoietin-like...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 second quarter ended March 31, 2018.
In recent trading, shares of Arrowhead Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $7.75, changing hands for $7.77/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present preclinical data on ARO-ANG3 and ARO-APOC3, its two candidates targeting cardiometabolic diseases, and ARO-ENaC, formerly referred to as ARO-Lung1, its first candidate to...
Investors in Arrowhead Pharmaceuticals Inc saw new options become available this week, for the December 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 8, 2018, at 4:30 p.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present clinical and pre-clinical data on the company's investigational medicines for the treatment of chronic hepatitis B infection (ARC-520 and...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2 clinical study of ARO-HBV, which is being developed as a potentially curative therapy for patients with...
In recent trading, shares of Arrowhead Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $7.30, changing hands for $7.32/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 16, 2018, the Board of Directors approved "inducement" grants to six new employees...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-AAT, which is being developed as treatment for a rare genetic liver disease associated...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the company will make a presentation at the following upcoming event: Barclays Global Healthcare Conference - Miami, March 13, at 1:35 p.
Investors in Arrowhead Pharmaceuticals Inc saw new options become available this week, for the April 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new April 20th contracts and identified one put and one call contract of particular interest.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and from the local Ethics Committee to proceed with a...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to ARO-AAT, Arrowhead's second-generation investigational medicine for...
In recent trading, shares of Arrowhead Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $5.38, changing hands for $5.47/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and from the local Ethics Committee to proceed with a...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 first quarter ended December 31, 2017.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Friday, February 9, 2018, at 4:30 p.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 22, 2018 it closed the previously announced underwritten public offering of 11,500,000 shares of its common stock, which included shares issued...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price of $5.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement.
